Pharvaris NV, a late-stage biopharmaceutical company specializing in oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, has announced its intention to offer and sell $150 million of ordinary shares in an underwritten public offering. The offering will be conducted by joint book-running managers Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen. Pharvaris also plans to grant underwriters a 30-day option to purchase an additional $22.5 million of shares. The net proceeds are intended to fund research and development for late-stage clinical programs, establish a sales and marketing team in the U.S., cover related commercialization expenses, and for general corporate purposes. The offering is contingent on market conditions, and there is no assurance on its completion or the final terms.